<DOC>
	<DOCNO>NCT00004190</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine gemcitabine oxaliplatin treat patient refractory locally advanced metastatic pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine Plus Oxaliplatin Treating Patients With Refractory Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety tolerability gemcitabine plus oxaliplatin patient refractory metastatic locally advanced pancreatic cancer ( phase I portion study close 7/5/00 ) . II . Determine objective tumor response rate combination regimen patient population . OUTLINE : This dose escalation efficacy study . Patients receive gemcitabine IV 30 minute day 1 8 immediately follow oxaliplatin IV 2 hour day 1 . Treatment repeat every 3 week . Patients achieve stable disease , partial response , regressive disease continue therapy . Patients achieve complete response two consecutive evaluation receive additional 2 course therapy . Phase I ( close 7/5/00 ) : Cohorts 3-6 patient receive escalate dos gemcitabine oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Phase II : Patients receive MTD gemcitabine oxaliplatin phase I . Patients follow every 3 month 1 year , every 6 month 4 year . PROJECTED ACCRUAL : A total 32-52 patient ( 12 patient phase I ( phase I close 7/5/00 ) 20-40 phase II ) accrue study within approximately 11-28 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ductal undifferentiated primary pancreatic cancer standard curative therapy exist Progressive locally advance disease combine chemotherapy radiotherapy OR Not candidate combined therapy OR Metastatic disease No islet cell , acinar cell , cystadenocarcinomas Measurable evaluable disease No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT great 2.5 time ULN Renal : Creatinine great ULN OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina No cardiac arrhythmia Other : No uncontrolled illness No active infection No allergy platinum compound , gemcitabine , antiemetics No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No evidence neuropathy except preexist grade I II Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy immunotherapy No concurrent immunotherapy Chemotherapy : No prior chemotherapy metastatic disease At least 6 month since prior adjuvant chemotherapy , include cisplatin gemcitabine , radiosensitization locally advance disease No prior cisplatin gemcitabine locally advance disease No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 25 % bone marrow No concurrent radiotherapy Surgery : Not specify Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>duct cell adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>